- Lapatinib in second line treatment of metastatic HER2+ breast cancer2012 | First Faculty of Medicine
- Trastuzumab deruxtecan: strong player in the field of metastatic HER2 positive breast cancer2022 | First Faculty of Medicine
- New agent to enhance targeted therapy of metastatic HER2+ breast cancer - pertuzumab2013 | First Faculty of Medicine
- Using 'Costs States' in a Semi-Markov Model to Estimate Cost-Effectiveness with an Illustration for Metastatic HER2 Breast Cancer in the Czech RepublicPublication without faculty affiliation
- The Cost-Effectiveness of Pertuzumab for the Treatment of Metastatic HER2+ Breast Cancer in Czechia: A Semi-Markov Model Using Cost States2023 | Faculty of Social Sciences
- Using 'Costs States' in a Semi-Markov Model to Estimate Cost-Effectiveness: an Illustration for Metastatic HER2 Breast Cancer in the Czech Republic2020 | Faculty of Social Sciences
- Metastatic HER2-positive breast cancer - a new standard of treatment2015 | First Faculty of Medicine
- Complete and long-term response of HER2 positive locally highly advanced metastatic breast cancer - case report2019 | Third Faculty of Medicine